IL23R and myeloid sarcoma: Romme Christensen et al., demonstrated that immune cells in peripheral blood from progressive MS patients presented a higher level of activation with increased frequencies of ICOS+ TFH cells and changes in surface phenotype with a larger quantity of IL-23 receptor expression on (IL23R)+CD4+ T cell surface [22].